
|Videos|October 13, 2021
The Future of Pediatric Pneumococcal Vaccines
Musey addressed any gaps and limitations that researchers should be focusing on in future studies and what he hopes to see for the future of pneumococcal vaccines and this disease.
Advertisement
Pharmacy Times spoke with Luwy Musey, executive director in biologics and vaccines clinical research at Merck, about the results from two phase 3 pediatric studies surrounding pneumococcal disease that was presented at the IDWeek 2021 conference.
Musey addressed any gaps and limitations that researchers should be focusing on in future studies and what he hopes to see for the future of pneumococcal vaccines and this disease.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
4
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
5


















































































































